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Abstract: Psoriasis is a chronic inflammatory disease affecting 2% to 3% of the population in 
Western countries. Psoriasis is associated with limited quality of life, cardiovascular disease, 
and depression. The approval of injectable biological agents has revolutionized the management 
of moderate to severe psoriasis. Adalimumab is a human monoclonal antibody against tumor 
necrosis factor (TNF) alpha approved for moderate-to-severe plaque-type psoriasis and psoriatic 
arthritis (PsA). This systematic review summarizes the evidence concerning the efficacy, clinical 
effectiveness, safety, and cost-effectiveness of adalimumab in the treatment of psoriasis. Five 
randomized controlled trials demonstrated the efficacy of adalimumab in moderate-to-severe 
plaque-type psoriasis and PsA with PASI-75 response rates of 53% to 80% and ACR-20 
response rates of 39% to 58% after 12 to 16 weeks of treatment. In clinical practice patients 
who have not responded to one TNF antagonist may respond to another TNF antagonist. 
Adalimumab has similar or better cost-effectiveness than other biologics, but is less efficient 
than methotrexate and cyclosporine. Adalimumab is generally well tolerated. Patients should 
be evaluated for active/latent tuberculosis, serious infections, and other contraindications prior 
to initiation of adalimumab therapy. Future studies should investigate the comparative efficacy 
of adalimumab and other biologic and prebiologic agents. Recently established registries will 
yield additional data on the effectiveness and long-term safety of adalimumab.
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Introduction
Psoriasis is an immune-mediated chronic inflammatory disease affecting approximately 
2% to 3% of the population in Western countries.1 Among several clinical phenotypes 
chronic plaque-psoriasis is most frequent and accounts for about 90% of cases.1,2 
Psoriasis may cause substantial problems in everyday life.3 Several studies suggested 
that patients with severe psoriasis have an increased risk for cardiovascular disease, 
depressive illness, and a decreased life expectancy.4–9 Currently incurable, psoriasis 
causes remarkable direct costs, work limitations and productivity loss.2,10–12
Systemic treatments are limited to patients with moderate-to-severe psoriasis in 
whom the activity of skin lesions and concurrent symptoms cannot be sufficiently 
controlled with topical treatments and with phototherapy.13–15
The history of treatment of psoriasis in past decades reflects uncertainty especially in 
terms of the pathogenesis of the disease. For example, the presence of large granulocyte 
accumulation and evidence of increased LTB4 in involved skin, discovered in the 
1980s, and later hyperexpression of interleukin IL-8 suggested at that time that both 
mediators could play a crucial role in psoriasis (so-called ‘neutrophilic dermatosis’). Biologics: Targets & Therapy 2009:3 304
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However, clinical trials with LTB4 or IL-8 antagonists were 
disappointing and showed no relevant antipsoriatic effects. 
In the mid 1980s intense investigation on cytokine production 
by T-cells led to the development of the T-helper 1/T-helper 
2 paradigm.16 The shift from psoriasis as neutrophilic 
dermatosis to ‘T-cell-mediated disease’ finally came, among 
others, from the convincing clinical results of ciclosporine. 
In addition, a substantial body of experimental evidence 
demonstrated that indeed the T-cell has to be seen as a key 
effector cell type in psoriatic inflammation (eg, SCID mice 
experiments). Parallel advances in research converged 
on proinflammatory cytokine tumor necrosis factor alpha 
(TNFα). Our knowledge about TNFα as a key cytokine has 
led to therapies targeting selective TNFα in psoriasis and 
other immune-mediated inflammatory diseases, in which 
lesional and systemically elevated levels of TNFα have 
been found. In this line rapid and substantial improvement 
of psoriasis and PsA by TNFα antagonists has been shown. 
On the other hand CD4+ T cells have been subdivided into 
different subsets, largely on the basis of the cytokines they 
generate. Such subsets include Th1, Th2, and regulatory 
T cells (Tregs). Recently another population of T cells has 
been described that is characterized by production of IL-17.17 
In this context the heterodimeric IL-12/IL-23 have been 
found to play a major role in determining the differentiation 
of Th1 and Th 17 cells. Thus, targeting IL-12/23 p40 has led 
to a novel therapeutic approach as evidenced in numerous 
clinical trials in patients with psoriasis by use of monoclonal 
antibodies like ustekinumab or ABT874.18–20 In summary, 
in the past 15 years much progress has been made in new 
exciting treatment modalities for psoriasis and PsA.
Today, three TNFα antagonists are registered for treating 
psoriasis and PsA (etanercept, infliximab, adalimumab). A novel 
human TNFα monoclonal antibody is expected to be approved 
for psoriatic arthritis in the near future (golimumab).
According to the T cell inactivating monoclonal anti-β2 
integrin lymphocyte function-associated antigen-1 antibody 
efalizumab, recently the EMEA’s Agencies Committee for 
Medicinal Products for Human Use (CHMP) has reviewed all 
available data on safety and effectiveness of efalizumab and 
recommended in a press release on February 19, 2009 that 
the marketing authorization for the drug should be suspended 
in the EU.21 One important issue for this decision was the 
occurrence of progressive multifocal leucencephalopathy 
(PML) in patients treated with efalizumab.21 As alefacept – 
another T cell inhibitor – is not approved in EU (except 
Switzerland), there is as yet no biologic T cell inhibitor 
available for treating psoriasis. Therefore, TNFα inhibitors 
are currently the most important drugs in the therapeutic 
management of psoriasis and PsA. Because of the therapeutic 
importance of the family of TNFα antagonists among several 
medical disciplines such as rheumatology, gastroenterology, 
and dermatology, we intend to give a critical review about 
clinical efficacy and safety of adalimumab as a fully human 
monoclonal IgG1 TNFα antibody, especially in psoriasis.
TNFα
TNFα belongs to the TNFα super family that constitutes at 
least 20 proteins.22 According to the revised nomenclature 
proposed by Schottelius et al TNFα is denoted by the acronym 
TNFSF 2 (tumor necrosis factor super family number 2).22 
From a clinical perspective, TNFα is a general term that 
includes soluble TNFα (sTNFα) and transmembrane TNFα 
(tmTNFα).
At low concentrations in tissues TNFα is thought to have 
beneficial effects such as prevention of infections. At high 
concentrations TNFα can lead to excess inflammation and organ 
injury. In a number of diseases TNFα is generally considered 
to be a proinflammatory cytokine. Activities ascribed to TNFα 
in psoriasis are described in detail elsewhere.23–34
Newly synthesized pro-TNFα is expressed on the plasma 
membrane as a 26 kDa protein and is thereafter cleaved in 
the extracellular domain by the TNFα-converting enzyme 
(TACE, syn. ADAM 17) to release a mature soluble 17 kDa 
protein as monomer.35 For biological activity trimerization 
is required, so that the generation of TNFα homotrimers 
with 51 kDa is realized by self-aggregation. The biological 
response of TNFα is mediated through two structurally 
distinct receptors:
Type 1 (TNFR1, syn.: p60, p55, CD 120a) and
Type 2 (TNFR2, syn.: p80, p75, CD 120b).35
Both receptors represent transmembrane glykoproteins with 
cysteine-rich repeats in the extracellular N-terminal domain.36 
Nearly all nucleated cells express TNFα receptors, whereas 
their distribution varies with cell type. The receptors can be 
cleaved from the cell surface by enzymes of the matrix metallo-
proteinase family in response to inflammatory signals. The gen-
eral biological effects of the major proinflammatory cytokine 
TNFα exhibit a wide diversity of functional activities.22,36,37
The significance of TNFα especially in psoriasis and 
PsA has been shown in numerous experimental and clinical 
investigations.22
1.  Increased levels of TNFα in lesional psoriatic skin;
2.  Increased TNFα mRNA expression in peripheral blood 
mononuclear cells of psoriatic patients;Biologics: Targets & Therapy 2009:3 305
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3.  Increased plasma concentration levels of TNFα as 
bioactive trimeric molecule in psoriatic patients;
4.  Differential expression of TNFR 1 and TNFR 2 in normal, 
uninvolved, and lesional skin of psoriasis patients.
However, from the clinical perspective the most 
impressive issue is that neutralization of TNFα in psoriasis 
by TNFα antagonists results in a high grade of amelioration 
of disease activity. Thus, clinical trials and practice have, 
in turn, strongly implicated TNFα in the pathogenesis of 
psoriasis and PsA.38
Adalimumab: structure  
and mechanism
Adalimumab, firstly described in the literature under 
the laboratory name D2E7, is a recombinant human 
immunoglobulin (IgG1) monoclonal antibody containing 
only human peptide sequences. Originally it was developed 
by BASF Pharma (Ludwigshafen Germany) to create a fully 
human monoclonal antibody with the goal of decreasing 
the antigenicity in order to achieve a greater therapeutic 
potential.39
Adalimumab is indistinguishable in structure and 
function from naturally occurring human IgG1. It is produced 
by phage display technology and consists of 1330 amino 
acids with a molecular weight of approximately 148 kDa. 
The terminal half-life is about 14 days.40–43 Relevant 
pharmacokinetic parameters of adalimumab are summarized 
in Table 1.
Adalimumab has a very high specificity and affinity for 
TNFα. It does not bind to or inactivate lymphotoxin α (TNFβ). 
The antibody binds to soluble and membrane bound TNFα 
in a dose-dependent manner before TNFα interacts with the 
p55 and p75 cell surface TNFα receptors. By preventing the 
binding of TNFα to its specific receptors, adalimumab blocks 
the proinflammatory activity of the cytokine. The ability of 
adalimumab to neutralize TNFα bioactivity was demonstrated 
in different in vitro cell systems. In vitro, adalimumab lyses 
surface TNFα-expressing cells in the presence of complement. 
Molecular analyses reveal that adalimumab forms stable 
trimer complexes with TNFα consisting of alternating three 
adalimumab and three TNFα molecules with the molecular 
weight of 598 kDa.44 It has been shown that adalimumab 
modulates responses that are induced or regulated by 
TNFα, including expression of adhesion molecules, serum 
concentrations of cytokines, matrix metalloproteinases, reac-
tive oxygen species of polymorphonuclear neutrophils, and 
dendritic cells in psoriatic plaques.41 Adalimumab has no effect 
on skin UV response in patients suffering from rheumatoid 
arthritis.45 In summary, these findings of characteristic 
properties of adalimumab all are in line with preclinical 
demands of a therapeutically useful TNFα antagonist. Non-
clinical toxicological assessment of adalimumab included 
studies in several animal species (eg, mice, rat, cynomolgus 
monkeys). These studies demonstrated a safe toxicologi-
cal profile providing a significant safety above dose levels 
investigated in clinical trials. Moreover, adalimumab did not 
show any signals for inducing mutagenicity in the Ames test 
or cause clastogenicity in vivo in mice.40–43
Methods
We systematically reviewed all published articles reporting 
original data on the efficacy of adalimumab for psoriasis in 
the setting of randomized controlled trials (RCT), its clinical 
effectiveness in daily practice (with n  30), its efficiency/
cost-effectiveness, as well as its safety and tolerability as 
reported in RCTs and in selected case reports. Additionally, 
we reviewed all pharmaco-genetic studies assessing genetic 
predispositions for response to adalimumab treatment of 
psoriasis patients.
Relevant articles were identified searching Medline from 
its inception until January 2009 for combinations of the 
search terms “psoriasis” and “adalimumab”. Animal studies 
were excluded. One investigator (JS) searched, reviewed, 
and abstracted data. Relevant data were abstracted using a 
standardized data abstraction form which was pilot tested 
for this systematic review. Primary measure of the efficacy 
of adalimumab in the treatment of plaque-type psoriasis 
was the proportion of patients with at least 75% reduction 
in psoriasis area severity index (PASI-75 response rate).46 
The primary measure of the efficacy of adalimumab in the 
treatment of PsA was the proportion of patients with at least 
20% improvement according to the American College of 
Table 1 Pharmacokinetic properties of adalimumab40–43
Parameter Value
  Absolute bioavailability 64%
  Time to maximum concentration 131 ± 56 hours
  Maximum serum concentration 4.7 ± 1.6 µg/mL
  volume of distribution 4.7 to 6.0 L
  Steady-state through concentration ∼5 mg/mL
  Total body clearance 0.18– 0.27 ml/min
  Terminal half-life ∼14 days
Time to
  initial response 1–7 days
  Peak response Within 3 monthsBiologics: Targets & Therapy 2009:3 306
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Rheumatology (ACR) criteria (ACR-20 response rate).47 
Additionally, PASI-50 and PASI-90 response rates and 
ACR-50 and RCA-70 response rates are reported from 
RCTs investigating adalimumab in patients with plaque-type 
psoriasis and PsA, respectively. Patient-reported outcomes 
such as the effect of adalimumab therapy on health-related 
quality of life, illness-related stress, disability, depressive 
symptoms were also abstracted from RCTs. Evidence from 
effectiveness studies and from economic evaluations was 
summarized using the endpoints used in the different studies 
identified. Adverse events and withdrawals were summarized 
as mean monthly incidence rates.
No external sponsor was involved in this study. No 
persons other than the authors of this manuscript were 
involved in the design, analysis, and interpretation of data, 
in the writing of the report, and in the decision to submit the 
article for publication.
Results
We identified a total of 201 articles, 102 of which were 
reviews not reporting original data. From the remaining 99 
papers we included
-  5 RCTs (14 papers48–61) assessing the safety and efficacy 
of adalimumab for plaque-type psoriasis and/or PsA,
-  3 studies62–64 investigating the clinical effectiveness 
of adalimumab for patients with psoriasis in daily 
practice,
-  2 pharmaco-genetic studies65,66 reporting an association 
of different gene-polymorphisms and response to 
adalimumab treatment for psoriasis,
-  3 economic evaluations67–69 looking at the cost-effectiveness 
of adalimumab treatment for psoriasis, and
-  16 case reports/case series70–85 discussing the safety 
of adalimumab and adverse events possibly related to 
adalimumab therapy administered for psoriasis.
Efficacy of adalimumab in the treatment 
of plaque-type psoriasis and PsA
Table 2 summarizes relevant data from the RCTs identified. 
All RCTs exclusively included adults with moderate-to-severe 
plaque-type psoriasis and/or PsA.
Three studies assessed the efficacy of adalimumab 
in moderate-to-severe plaque-type psoriasis.48–50 After 
12 weeks of double-blind treatment with adalimumab 40 mg 
and adalimumab 40 mg every other week (eow), 80% and 
53% of patients showed at least 75% PASI improvement, 
respectively, whereas only 4% of the patients who had 
received placebo met the PASI-75 response criterion.48 
Based on the intention-to-treat population, PASI-75 response 
rates the end of the open-label extension study until week 60 
after treatment were 64% after treatment with adalimumab 
40 mg weekly and 56% in patients receiving adalimumab 
40 mg eow.48
In a phase III double-blind, placebo-controlled RCT 
including 1212 patients with moderate-to-severe plaque-type 
psoriasis, Menter et al reported PASI-75 response rates of 
71% after 16 weeks and 70% after 24 weeks of treatment with 
adalimumab 40 mg eow.49 To investigate the loss of response 
within 19 weeks after discontinuation of adalimumab 
therapy, patients responding to adalimumab (ie, met the 
PASI-75 response criterion) in week 33 were re-allocated 
and continued double-blind treatment with adalimumab 
or were switched to placebo and treated accordingly for 
the following 19 weeks (until week 52). Loss of response, 
defined as  PASI-50 and 6 Point increase in PASI, was 
observed in 28% of patients switched to placebo and 5% of 
patients continuing adalimumab therapy.49 This indicates 
that continuous treatment with adalimumab is required in 
many patients to maintain sustained effectiveness and that 
adalimumab does not appear to modify the course of plaque-
type psoriasis in a way that long-term remissions are to be 
expected, at least not in all patients.
The only head-to-head trial comparing adalimumab 
against another systemic treatment for moderate-to-severe 
psoriasis investigated the comparative efficacy of adalimumab 
40 mg eow (n = 108) versus methotrexate (MTX; 7.5 mg 
orally, increased as needed and as tolerated to 25 mg 
weekly; n = 110) versus placebo (n = 53). After 16 weeks of 
double-blind treatment, 80% of adalimumab-treated patients 
achieved PASI-75, compared with 36% for methotrexate 
and 19% for placebo PASI-50 and PASI-90. Response rates 
were also higher in patients receiving adalimumab than in 
those treated with MTX, so that the authors concluded that 
adalimumab demonstrated significantly superior efficacy in 
plaque-type psoriasis compared with MTX.50 This conclusion, 
however, was criticized because the trial was designed as 
a noninferiority study, the demonstration of superiority of 
adalimumab over MTX being based on a post-hoc analysis. 
From a methodological perspective, it can therefore only be 
concluded that adalimumab is not worse than MTX, although 
the reported data suggest that it may be superior.55
Two double-blind, placebo-controlled trials were 
conducted to investigate the efficacy of adalimumab 
40 mg eow in patients with moderately to severely active 
PsA and a history of inadequate response to nonsteroidal 
anti-inflammatory drugs (Table 2).56–59Biologics: Targets & Therapy 2009:3 307
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Genovese et al reported ACR-20 response rates of 39% 
after treatment with adalimumab for 12 weeks versus 16% for 
placebo (p = 0.01). At week 24, after an open-label extension 
period, 65% of patients met the ACR20 response criterion.59
Another study published by Mease et al57 demonstrated 
that adalimumab significantly improves joint manifestations 
as assessed by the ACR criteria and also inhibited structural 
changes on radiographs. At week 12, 58% of the adalimumab-
treated patients achieved an ACR-20 response, compared with 
14% of the placebo-treated patients. Similar response rates 
were maintained in the adalimumab group until week 104.58 
At week 24, the mean change in the modified total Sharp score 
was –0.2 in patients receiving adalimumab and 1.0 in those 
receiving placebo indicating that adalimumab inhibits the 
progression of structural joint changes attributed to PsA.57
Patient-reported outcomes
Each randomized controlled trial identified also assessed a set 
of patient-reported outcomes as secondary endpoints, which 
were reported in detail in secondary publications.51–54,60,61 One 
secondary analysis utilizing data from an RCT49 indicated that 
clinical efficacy of adalimumab therapy translates into improved 
wellbeing and health-related quality of life as assessed by the 
Short Form-36 (SF-36) Health Survey86,87 scores which showed 
improvements both in physical and in mental health after 
16 weeks of adalimumab therapy.51 The head-to-head study 
comparing adalimumab with MTX in patients with plaque-type 
psoriasis50 indicated that adalimumab leads to an improved 
quality of life as assessed by means of the Dermatology Life 
Quality Index (DLQI)88 and the EuroQOL 5D (EQ-5D)89 
and is also beneficial for disease symptoms such as pruritus 
and pain.52 It has also been shown that adalimumab therapy 
increases work productivity and activity53 which is particularly 
important in light of the known adverse effect of psoriasis on 
work productivity and high corresponding indirect cost.12
Pooled data from different trials totaling 1469 patients with 
moderate to severe plaque-type psoriasis indicated that the degree 
of PASI response correlates with the improvement of quality 
of life, PASI-90 or PASI-100 responders experiencing greater 
improvements in DLQI total score than PASI-75 responders.60
For patients with PsA it has been demonstrated that 
adalimumab therapy decreases functional impairment, 
health-related quality of life, fatigue, and pain.61
effectiveness in clinical practice
Data on studies evaluating the clinical effectiveness of 
adalimumab for plaque-type psoriasis and/or for PsA in daily 
clinical practice are summarized in Table 3.
Papoutsaki et al assessed the effectiveness of adalimumab 
therapy in 30 patients affected by moderate-to-severe 
plaque-type psoriasis with or without PsA, who had failed to 
respond to, did not tolerate, or had contraindications against 
the other biologic and nonbiologic treatment options for 
psoriasis.62 Adalimumab 40 mg once a week was administered 
in monotherapy for 24 weeks with assessment of PASI and 
Ritchie articular index (the latter only in the subset of patients 
with PsA) at week 12 and 24. PASI-75 response rates at 
week 12 and 24 were 87% and 83%, respectively. At week 
24, arthritis had significantly improved from mean baseline 
Ritchie articular index 10 to 2.62 Although this study is limited 
by open-label treatment, the absence of a control group, 
and missing information on concurrent topical antipsoriatic 
treatment, it gives good evidence that adalimumab effectively 
controls plaque-type psoriasis and PsA in many patients 
refractory to other biologic and conventional agents.
Heiberg et al compared the effectiveness of adalimumab, 
infliximab, and etanercept in patients with PsA, rheumatoid 
arthritis, and ankylosing spondylitis by means of the 1-year 
retention rates of the different medications.63 This is a very 
interesting approach as retention rates are a good global 
indicator for effectiveness, patient satisfaction, and 
tolerability. The analyses comprised 172 anti-TNFα treatment 
courses in patients with PsA (adalimumab n = 28; infliximab 
n = 48; etanercept n = 96). Withdrawal rates were lowest for 
adalimumab (14.3%) than for both other anti-TNFα agents 
approved at the time the study was conducted (infliximab 
25.0%; etanercept 24.0%). The authors also calculated 
hazard ratios for treatment termination with adjustments for 
age, sex, investigator's global assessment, and concomitant 
MTX therapy. Concomitant MTX therapy was associated 
with lower withdrawal rates of anti-TNFα agents. This 
analysis, however, was not restricted to adalimumab, but 
also considered etanercept and infliximab.63
A retrospective chart review including 49 patients 
moderate-to-severe plaque-type psoriasis indicated that 
88% and 78% of patients were considered as “clear” or 
“almost clear” according to physician’s global assessment 
of disease severity after 3 and 12 months of treatment with 
adalimumab 40 mg per week. According to this study, 
long-term effectiveness of adalimumab was independent of 
previous biological treatment. Response rates after 12 months 
of adalimumab therapy in the subgroup of patients previously 
treated with infliximab and/or etancercept was 78%. Within 
the 12-month study period 5 patients (10%) discontinued 
adalimumab because of lack of effectiveness.64 The main 
drawback of this study is that only patients observed for at least Biologics: Targets & Therapy 2009:3 309
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12 months were included, which may have caused selection 
bias with consecutive overestimation of effectiveness.
Pharmaco-genetic studies
We identified two pharmaco-genetic investigations evaluating 
the response to anti-TNFα agents including adalimumab with 
TNFα-gene polymorphism and Fcγ-receptor polymorphism, 
respectively.65,66 Based on a clinical sample of 30 patients 
with rheumatoid arthritis and 5 patients with PsA, Tutuncu 
et al reported that the response to anti-TNFα treatment 
varied with regard to the Fcγ-receptor receptor type IIIA-158 
genotype, the low-affinity F/F homozygous genotype being 
significantly associated with response to TNFα-inhibitor 
therapy (p  0.01).66 Seitz et al observed in another clinical 
sample of patients with PsA, rheumatoid arthritis, and 
ankylosing spondylitis treated with adalimumab (n = 10), 
infliximab (n = 63), or etanercept (n = 13), respectively, 
that treatment response significantly differed with regard to 
the G-to-A polymorphism at position -308 in the promoter 
of the TNFα-gene. All patients with the A/A genotype 
failed to respond to treatment, whereas good response was 
exclusively seen in patients with the G/G genotype.65 These 
studies are very promising and may help to better identify the 
subgroup of psoriasis patients with psoriasis benefiting most 
from adalimumab therapy. Replications of these promising 
findings and similar studies in patients with plaque-type 
psoriasis are necessary.
Safety and tolerability
Tables 3 and 4 summarize, respectively, safety data from 
clinical trials on adalimumab for psoriasis and case reports 
highlighting rare adverse reactions occurring in patients with 
psoriasis under adalimumab therapy, which may have been 
related to this agent.
The monthly incidence rate of injection site reaction ranged 
from 1.2%57 to 3.4%48 in clinical trials (Table 4). Within 
2 years of exposure to adalimumab 20/298 patients with PsA 
discontinued treatment because of adverse events.58 In this 
long-term study 3 patients (1.0%) died within the observation 
period, 2 of whom had myocardial infarction that was classified 
as probably not related to adalimumab, and 1 experienced 
sudden death after acute pulmonary edema that was classified 
as possibly related to adalimumab.58 No deaths were observed 
in other clinical trials included in this systematic review.48–50,59 
Interestingly, in the RCT by Genovese et al59 to assess the 
efficacy and safety of adalimumab for PsA, adverse events 
occurred significantly more frequently in patients receiving 
placebo than in those receiving adalimumab (p  0.01).
The specific side effects associated with anti-TNF 
therapy in general should be discussed at greater length. 
As discussed already, TNFα plays a central role in the 
inflammation and cellular immune response. TNFα is 
a cytokine of the innate immune system critical in the 
surveillance of malignancies and infections. Thus, anti-TNF 
agents, including adalimumab, may affect a patient’s defence 
against infections and malignancies.
In the setting of clinical trials, upper respiratory tract 
infections and nasopharingitis were observed more frequently 
in patients treated with adalimumab than in those receiving 
placebo (Table 4).
One area that has been of particular concern with the advent 
of anti-TNFα biologic therapies has been the reactivation of 
latent tuberculosis (Tb).90,91 TNFα is an important cytokine 
in preventing Tb infection and in keeping latent Tb infection 
from becoming active disease. Following the National 
Psoriasis Foundation consensus statement on screening for 
latent Tb in patients with psoriasis treated with systemic 
and biologic agents, it is therefore of utmost importance to 
appropriately screen all patients for latent Tb infection prior 
to initiating any immunologic therapy. The tuberculin skin 
test is still used most frequently as a screening tool for latent 
Tb. This strategy, however, is limited by the poor specificity 
of the tuberculin skin test in populations vaccinated with 
bacille Calmette-Guérin (BCG) and its low sensitivity in 
immunosuppressed persons. Two blood tests (T-SPOT.
TB and QuantiFERON-TB Gold), based on detection of 
IFN-γ released by T cells in response to 2 unique antigens 
that are highly specific for Mycobacterium tuberculosis 
but absent from BCG vaccine and most nontuberculous, 
mycobacteria offer an improvement on the skin test. Both 
tests are not confounded by prior BCG vaccination and also 
have operational advantages over the skin test because no 
return visit is required, results are available by the next day, 
and repeated testing does not cause boosting.92,93
Delaying immunologic therapy until latent Tb infection 
prophylaxis is completed is preferable.94 In the RCTs 
included in this review, patients were screened for latent Tb 
prior to inclusion and not eligible if Tb was suspected unless 
Tb treatment had been initiated already. Nevertheless, 3 cases 
of Tb were observed in the 5 trials included in this review 
(Table 4), indicating that caution should prevail in patients 
receiving adalimumab for psoriasis even in the absence of 
signs for latent Tb prior to treatment initiation. Other severe 
infections observed in clinical trials assessing adalimumab 
for psoriasis included coccidioidomycosis (n = 1)48 and viral 
meningitis (n = 1).56–58 We did not identify any case reports Biologics: Targets & Therapy 2009:3 311
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pointing at opportunistic infections in psoriasis patients 
treated with adalimumab. In patients receiving adalimumab 
for rheumatoid arthritis, however, a series of cases with 
Legionella pneumophila pneumonia has been reported 
recently.79
Table 4 summarizes the cases of malignant disease 
observed in patients treated with adalimumab in RCTs. 
For most tumor entities only single cases were observed, 
allowing no conclusions about the association with 
adalimumab. A total of 10 cases of nonmelanoma skin 
cancers and 3 cases of malignant melanoma were observed 
(Table 4). Fulchiero et al reported a case of late recurrence of 
locoregional metastatic melanoma shortly after the initiation 
of adalimumab for rheumatoid arthritis.73 Other cases of 
late recurrence of melanoma in psoriasis patients receiving 
anti-TNFα treatment have been reported (summary in73), 
so that patients with a history of melanoma have been not 
eligible in trials assessing adalimumab for psoriasis.48–50,57,59 
Although the incidence of melanoma and nonmelanoma 
skin cancers in clinical trials is relatively high, it may still be 
explained by chance. Development of malignant melanoma 
and nonmelanoma skin cancer is a general concern for 
patients undergoing immunosuppressive therapy and/or 
phototherapy.95–99 Because patients receiving adalimumab 
were typically exposed to other immunosuppressants/
immune-modifying agents before, the role of adalimumab 
in the reported cases of skin cancer remains unclear. Until 
representative safety data are available, each patient’s 
individual risk factor profile for nonmelanoma skin cancer 
and melanoma history should be carefully considered before 
a decision is taken on whether adalimumab (or any other 
TNFα therapy) is appropriate.
Cases of demyelination, optic neuritis, and multiple 
sclerosis (MS) have not been observed in RCTs of 
adalimumab for plaque-type psoriasis or PsA (Table 4). 
We identified 2 case reports which document a possible 
association of adalimumab treatment with the development 
of demyelination71 and optic neuritis (Table 5).72 This 
association is plausible, because several reports of MS or 
associated symptoms have been reported under treatment 
with other anti-TNFα agents, particularly with etanercept, 
but also with infliximab.71,100 A placebo-controlled RCT 
evaluating the effect of lenercept, a recombinant TNF 
receptor p55 immunoglobulin fusion protein, in patients 
with MS showed an increase in exacerbations and more 
severe neurologic deficits in patients receiving lenercept 
compared to placebo.101 Prospective registries are necessary 
to clarify if and to what extend adalimumab is associated 
with an increased risk of central nervous demyelination. 
Until then, doctors should inform patients about this possible 
association, avoid the use of adalimumab in patients with a 
history of MS, and be aware of early signs of demyelinating 
disease such as weakness in the limb(s), paresthesia, visual 
blurring, and ataxia.
Deng et al reported 5 cases of interstitial granulomatous 
dermatitis developing in patients treated with TNFα 
antagonists including adalimumab (Table 5).78 Although it 
remains unclear from the reported data whether adalimumab 
caused this reaction or whether it was just a coincidence, 
interstitial granulomatous dermatitis should be considered 
in the differential diagnosis of annular lesions occurring in 
patients treated with adalimumab.
Numerous reports of the induction or worsening of 
psoriasis in patients treated with TNFα antagonists indicate 
that this is not a rare phenomenon.81,82 Collamer et al reviewed 
all cases of pustular psoriasis occurring under anti-TNFα 
therapy and concluded that new-onset psoriasis may occur 
any time after initiation anti-TNFα therapy and is often of 
an uncommon morphology or localization.102 We identified 
2 cases of new onset generalized pustular psoriasis in patients 
receiving adalimumab for PsA80 and pustular psoriasis of the 
scalp,81 respectively. The etiology of this adverse reaction 
is not completely understood yet. It has been suggested that 
this paradoxical response appears to involve a disruption 
in cytokine balance following TNFα inhibition, resulting 
in the upregulation of plasmacytoid dendritic cells and 
the subsequent production of unopposed interferon-alpha, 
following a triggering event in predisposed individuals.102 
Notably, adalimumab has not only been reported to cause 
pustular psoriasis, but also to be effective in the treatment 
of recalcitrant generalized pustular psoriasis in adults and 
adolescents.83,84
Adalimumab-induced psoriasis does not necessarily 
require therapy cessation. Particularly in patients with 
severe PsA and good clinical response to adalimumab, we 
recommend aggressive treatment of the skin lesions and 
discontinuation of adalimumab only in cases unresponsive 
to topical antipsoriatic treatment.
In patients treated with adalimumab for rheumatoid 
arthritis or psoriasis several cutaneous adverse reactions 
other than new onset psoriasis may occur, including subacute 
cutaneous lupus erythematosus, vitiligo, urticaria, eczema, 
dermatitis herpetiformis, perivascular neutrophilic dermatitis, 
tinea, alopecia areata, and pityriasis rosea.74,75,77,103–106 Most of 
these reactions were mild and did not require discontinuation 
of treatment. The development of these conditions shortly Biologics: Targets & Therapy 2009:3 313
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after the initiation of adalimumab treatment and the 
improvement/clearance after discontinuation of adalimumab 
suggests a causal relationship. However, most of these 
conditions are quite frequent in the general population, so that 
some of these reactions may have been coincidences rather 
than associations with adalimumab. Prospective registries 
are needed for further clarification.
Adalimumab is often prescribed to women of reproductive 
age, raising questions about its effect on pregnancy. 
The molecular structure of adalimumab permits little 
placental transfer during the first trimester, but placental 
transfer cannot be excluded during the second and third 
trimesters of pregnancy.107 In animal studies, no evidence 
of embryotoxicity or teratogenicity has been observed.70 
Human experience is still extremely limited, particularly in 
patients with psoriasis. One patient with rheumatoid arthritis 
became pregnant after receiving a single dose of adalimumab. 
She delivered a healthy infant at 32 weeks with no neonatal 
abnormalities and normal growth and development.70 In 
patients becoming pregnant while receiving anti-TNFα 
therapy the following perinatal complications were observed: 
prematurity, neonatal jaundice, neonatal urinary Escherichia 
coli infection, and adrenal congenital hyperplasia of probable 
hereditary origin.70 Therefore, caution should be taken when 
adalimumab or other anti-TNF agents are used in women 
with childbearing potential. Any cases of pregnancy under 
adalimumab should be collected in registries to be able to give 
evidence-based recommendations for consulting pregnant 
women under adalimumab therapy in the future.
Data on the safety of adalimumab and other TNFα 
antagonists in HIV-positive individuals and in patients with 
viral hepatitis are limited to few case series, which did not 
detect any significant clinical adverse effects attributed to 
anti-TNF treatment.108,109 However, systematic, studies and/
or prospective registries addressing the issue of safety of 
monoclonal antibodies targeted against TNFα in patients with 
chronic hepatitis and in HIV-positive individuals will be needed 
to properly assess the risks and benefits of anti-TNF treatment 
in these patients usually excluded from clinical trials.
Efficiency/cost-effectiveness  
of adalimumab for psoriasis
We identified 2 studies assessing the cost-effectiveness of 
adalimumab in plaque-type psoriasis. Sizto et al compared 
the long-term cost-effectiveness of biologic and nonbiologic 
treatment options for moderate to severe plaque-type 
psoriasis.68 Within the group of biologics adalimumab 
was most cost-effective, followed by etanercept. Despite 
lower efficacy, methotrexate and cyclosporine were more 
cost-effective than adalimumab due to the lower direct cost 
of these prebiologic systemic agents.68 Because data on the 
long-term effectiveness of the different agents approved for 
psoriasis are sparse, this analysis is limited by a number of 
assumptions based on expert opinions rather than published 
data. According to another health-economic evaluation of 
biologic agents for psoriasis Nelson et al assessed infliximab 
to be most cost-effective in the short-term biologic treatment of 
plaque-type psoriasis, followed by adalimumab.67 It has been 
reported, however, that the cost-effectiveness of biologics 
are observed to converge over the first year of treatment, so 
that extrapolating the results of the study by Nelson et al to 
longer treatment periods may not be accurate.67,69
Comment
In recent years, the development and approval of inject-
able biologic agents has revolutionized the management 
of moderate-to-severe plaque-type psoriasis and PsA. In 
contrast to T cell inhibitors, TNFα antagonists are providing 
concomitant benefits for the skin and joints.
Among these, adalimumab is the first fully human 
monoclonal antibody against TNFα.
Studies indicate that it is highly efficacious both in 
moderate-to-severe plaque type psoriasis and in severe PsA 
with significant improvements within 4 weeks.48–61 A recent 
meta-analysis indicated that adalimumab is superior to 
cyclosporine, efalizumab, and etanercept in the treatment of 
chronic plaque-type psoriasis.110 Based on published trials, 
infliximab leads to higher response rates than adalimumab 
within 12 to 16 weeks of treatment. However, a loss of 
efficacy over time has been observed in patients receiving 
infliximab, but does not appear to be an issue for adalimumab 
based on published data.110 One head-to-head study suggested 
that adalimumab is at least similarly efficacious and possibly 
more efficacious than MTX in the short-term treatment of 
moderate-to-severe plaque-type psoriasis.50,55
Managed care organizations are currently debating the 
appropriate use of biologic drugs for psoriasis.111,112 Given 
the widespread patient dissatisfaction with conventional 
treatments, the demand of treatment alternatives is high.10 
In all published RCTs clinical improvements translated into 
increased wellbeing, improved health-related quality of 
life, and improvements in other patient-reported outcomes. 
Future studies should investigate the comparative efficacy of 
adalimumab and other biologic and prebiologic agents.
Adalimumab treatment may be particularly beneficial for 
psoriasis patients who have failed multiple other biologic and Biologics: Targets & Therapy 2009:3 315
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nonbiologic systemic agents: effectiveness studies suggested 
that adalimumab is highly effective in the subset of patients 
not responding to other conventional of biologic treatments 
approved for psoriasis and that adalimumab therapy is more 
likely to be continued than treatment with other anti-TNFα 
agents. Concomitant MTX therapy should be considered 
particularly in cases of severe PsA.
Pharmaco-genetic investigations suggested that the response 
to anti-TNFα agents including adalimumab is modified by 
polymorphisms in the TNFα-gene and Fcγ-receptor gene.65,66 
These studies are very promising and may help to better identify 
the subgroup of psoriasis patients with psoriasis benefiting 
most from adalimumab therapy. Prior to the application of 
gene-polymorphism screening in clinical practice, however, 
replications of these promising findings and similar studies in 
patients with plaque-type psoriasis are warranted.
Economic evaluations indicated that adalimumab is one 
of the biologics with a more favorable cost-benefit profile.67–69 
One study suggested that adalimumab may be less efficient than 
methotrexate and cyclosporine.68 More studies with a longer 
time horizon and a more rigorous methodology considering 
also indirect costs are needed to better understand economic 
implications of a broader and possibly earlier use of biologics.
Despite significant theoretical risks, the safety profiles of 
TNFα antagonists such as adalimumab are remarkably good. 
Burmester et al summarized data on the safety of adalimumab 
from 19,041 patients exposed to adalimumab in 36 clinical trials 
in psoriasis, PsA, rheumatoid arthritis, ankylosing spondylitis, 
and Crohn's disease and concluded that the overall malignancy 
rates and the all-cause mortality rates for adalimumab-treated 
patients were as expected for the general population.113
Prior to initiation of adalimumab therapy patients should 
be evaluated for active/latent Tb, serious infections, and other 
contraindications.
Recently established registries are expected to yield 
more data on the safety and effectiveness of adalimumab in 
clinical practice soon.
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